Regeneron to request FDA clearance to use Covid antibody drug as a preventative treatment

Regeneron said a phase three clinical trial of the drug reduced the risk of symptomatic infections in individuals by 81%.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.